Skip To Main Content
Joann Peters on Muck Rack

Joann Peters

As seen in: Nature

Get in touch with Joann

Contact Joann, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

Publisher Correction: Adjuvant personalized multivalent neoantigen DNA vaccination for MGMT unmethylated glioblastoma: a phase 1 trial

|
By Elizabeth A. R. Garfinkle, Renzo Perales-Linares, Ryan C Gimple, Alexandra J. Livingstone, Kaleigh Roberts, Omar Butt, S. Peter Goedegebuure, Michael McLellan, Gue Su Chang, Jasreet Hundal, Jian Yan, Jaye B. Navarro, Sophia A. Paxton, Srestha Chattopadhyay, Neil Cooch, Alfredo Perales-Puchalt, Konstantina Stavroulaki, Sarah Rochestie, Joann Peters, Beth Junker, Jian L. Campian, Milan G. Chheda, Michael R. Chicoine, Albert Kim, Jon Willie, Gregory J. Zipfel, Joshua Dowling Verified, Christopher Miller, Obi L. Griffith, Malachi Griffith, William E. Gillanders, Katherine Miller Verified, Elaine R. Mardis, Niranjan Y. Sardesai, Gavin P. Dunn, Tanner Johanns
| Nature Verified
Correction to: Nature Cancer https://doi.org/10.1038/s43018-026-01163-w, published online 12 May 2026. In the version of the article initially published, in the top-left graph of Fig. 3b, the y-axis label was “CD4+CD69+ (%, delta)” but should have been “CD8+CD69+ (%, delta)”. In the top-right box of Fig. 5d, the label “Post-GNOS-PV01” should have read “Pre-GNOS-PV01”. These corrections have been made to the HTML and PDF versions of the article.
Open in Who Shared View Duplicates (7) Issue with article?

Adjuvant personalized multivalent neoantigen DNA vaccination for MGMT unmethylated glioblastoma: a phase 1 trial

|
By Elizabeth A. R. Garfinkle, Renzo Perales-Linares, Ryan C Gimple, Alexandra J. Livingstone, Kaleigh Roberts, Omar Butt, S. Peter Goedegebuure, Michael McLellan, Gue Su Chang, Jasreet Hundal, Jian Yan, Jaye B. Navarro, Sophia A. Paxton, Srestha Chattopadhyay, Neil Cooch, Alfredo Perales-Puchalt, Konstantina Stavroulaki, Sarah Rochestie, Joann Peters, Beth Junker, Jian L. Campian, Milan G. Chheda, Michael R. Chicoine, Albert Kim, Jon Willie, Gregory J. Zipfel, Joshua Dowling Verified, Christopher Miller Verified, Obi L. Griffith, Malachi Griffith, William E. Gillanders, Katherine Miller Verified, Elaine R. Mardis, Niranjan Y. Sardesai, Gavin P. Dunn, Tanner Johanns
| Nature Verified
Abstract Glioblastoma is a fatal disease with a median prognosis of 12–18 months. Recent studies have shown encouraging results using neoantigen-based vaccines to stimulate glioblastoma-directed immune responses, but overall immunogenicity has been low.
Open in Who Shared Issue with article?
See all 2 articles